Rockwell Medical faces a precarious outlook characterized by consistent revenue erosion, with quarterly figures falling from $28.3 million in 2024Q3 to $18.3 million by 2025Q4.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.34-44.7% vs -$0.23 | $18M-0.2% vs $18M |
Q2 2026 May 7, 2026 | -$0.40-300.0% vs -$0.10 | $17M-3.4% vs $18M |
Q2 2026 Mar 26, 2026 | -$0.10-125.0% vs $0.40 | $18M-1.4% vs $19M |
Q4 2025 Nov 12, 2025 | -$0.50-25.0% vs -$0.40 | $16M-1.9% vs $16M |
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the third quarter ended September 30, 2026 on Thursday, November 12, 2026.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Come visit Rockwell Medical in Booth #1049 at ASN Kidney Week 2026 at the Colorado Convention Center in Denver, CO.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--This marks the 3rd consecutive year that Rockwell Medical earned this recognition—climbing the ranks from #50 (2024) and #40 (2025) to #16 (2026).
Embecta (NASDAQ: EMBC - Get Free Report) and Rockwell Medical (NASDAQ: RMTI - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability. Profitability This table compares Embecta and Rockwell Medical's
Benchmark RMTI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Rockwell Medical, Inc. (RMTI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.73 | $30.51M | -6.02 | -31.76% | -7.33% | -14.03% | — | |
| $37.26 | $1.23B | -7.84 | -43.89% | -287.84% | -37.99% | — | |
| $1.78 | $790.67M | -12.42 | 60.24% | -159.09% | -37.8% | — | |
| $26.16 | $3.19B | 7.09 | 4.29% | 32.75% | — | — | |
| $103.63 | $12.29B | 26.18 | 37.55% | 26.93% | 544.26% | — | |
| $15.85 | $2.19B | -1.25 | -2.75% | -43.27% | -68.13% | 7.26% |
Rockwell Medical, Inc. (RMTI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Rockwell Medical, Inc. (RMTI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 13, 2026·SEC
Jul 20, 2026·SEC
Get notified when RMTI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rockwell Medical, Inc. (RMTI) stock FAQ — growth, dividends, profitability & financials explained
Rockwell Medical, Inc. (RMTI) reported $69.3M in revenue in fiscal year 2025, which is also its trailing twelve months. That is 1999% more than the $3.3M of fiscal year 1997.
Rockwell Medical, Inc. (RMTI) revenue fell by 21.1% over the trailing twelve months, compared with the twelve months before.
No. Rockwell Medical, Inc. (RMTI) reported a net loss of $5.1M over the trailing twelve months.
Rockwell Medical, Inc. (RMTI) had a return on equity (ROE) of -14.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Rockwell Medical, Inc. (RMTI) generated $1.5M in free cash flow over the trailing twelve months.
